We are world leaders in advanced wound management, orthopaedics and sports medicine technologies and solutions.
We serve our markets through three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. These business units are responsible for strategy and global marketing, and contain specialist sales and support teams dedicated to serving the specific requirements of healthcare systems.
We compete in global markets valued at more than $50 billion1 annually.
1. Data generated by Smith+Nephew based on publicly available sources and internal analysis and represents an indication of market shares and sizes.
The vision of our Advanced Wound Management business unit is to ‘Shape What’s Possible in Wound Care’. Through our extensive portfolio, designed to meet broad and complex clinical needs, we help healthcare professionals solve the challenges of preventing and healing wounds.
In Advanced Wound Care (AWC) our portfolio includes products that are designed to manage exudate and infection, protect the skin and prevent pressure injuries.
In Advanced Wound Bioactives (AWB), our products provide a unique approach to debridement, dermal repair, and tissue substitutes, with considerable evidence supporting their clinical application.
In Advanced Wound Devices (AWD), our portfolio helps improve healing outcomes in chronic wounds, reduce surgical site complications and facilitate preventative care for pressure injuries. Our devices include Negative Pressure Wound Therapy systems - both single-use and traditional (cannister-based) solutions, a controlled debridement Hydrosurgery System and a patient monitoring system supporting pressure injury prevention.
Our Orthopaedics business unit offers a leading portfolio of Hip and Knee Implants, robotics and digital-enabling technologies, driving procedural innovation and strengthened Trauma & Extremities portfolio.
Smith+Nephew’s Orthopaedics vision is to deliver innovative personalised solutions to customers that enhance clinical and economic outcomes in every care setting. Our innovative implants are designed to mimic natural movement and are manufactured using materials with a track record of longevity and performance.
Orthopaedics includes an innovative range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that improve accuracy and facilitate precision during the surgical procedure, and trauma products used to stabilise fractures and correct bone deformities.
In Orthopaedic Joint Reconstruction, which includes our Hip and Knee Implants and Other Reconstruction segments, we have a broad, clinically proven and differentiated portfolio. It includes our proprietary OXINIUM◊ Technology and our CORI◊ Surgical System, which is strongly positioned to take advantage of the trends towards robotics-assisted surgery and outpatient joint replacement seen across the segment.
In Trauma & Extremities, Smith+Nephew’s portfolio includes differentiated technology across the major categories of Plates and Screws, Intramedullary Nails, Hip Fracture, Limb Restoration, Extremities, and Shoulder Replacement.
Smith+Nephew’s Sports Medicine & ENT business unit leads with innovative procedural solutions to elevate the standard of care.
We operate in growing markets where unmet clinical needs provide opportunities for procedural and technological innovation. We have a rich history of product development in Sports Medicine, and our technologies, instruments and implants enable surgeons to perform minimally invasive surgery, treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip and small joints.
In Sports Medicine Joint Repair (SMJR), we develop products for rotator cuff repair (RCR) and instability repair in the shoulder to help address pain and restore function. In knee repair, our All Tears, All Repairs Meniscal Repair portfolio provides surgeons with unsurpassed options and possibilities for meniscal repair, a novel technology for knee cartilage and osteochondral defects, and a comprehensive ligament portfolio. Our hip preservation portfolio delivers a broad set of technologies and techniques addressing all capsular management needs. We are also committed to redefining healing potential in gluteus medius repair and capsular augmentation.
Our Foot and Ankle portfolio for soft tissue repair includes comprehensive solutions for ankle instability and Achilles reconstruction.
In Arthroscopic Enabling Technologies (AET), our products facilitate arthroscopic surgical procedures, providing a strong foundation of platforms and associated consumables, including visualisation, fluid management, COBLATION◊ technology and mechanical resection.
Our growing ENT business unit is driven by emerging therapies and changes in the point of care, mainly to the office setting, and increasing global access for these procedures.
We offer a portfolio of technologies focused on the unmet needs for both common and advanced procedures hat general and paediatric ENT surgeons perform today. These include tonsillectomies, epistaxis (severe nose bleeds) and tympanostomies (insertion of ear tubes).
In Ear, Nose & Throat (ENT) we provide low temperature technologies to remove tonsils and adenoids, epistaxis solutions and in-office solution for placement of tympanostomy or ear tubes.
Smith+Nephew operates in global markets valued at approximately US $50 billion.
These markets are shaped by strong long-term growth drivers and technology advancements as well as the increasing decentralisation of care and stretched healthcare budgets.